Cover Image
市場調查報告書

擴大性心肌病 : 開發平台分析

Dilated Cardiomyopathy - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 246011
出版日期 內容資訊 英文 60 Pages
訂單完成後即時交付
價格
Back to Top
擴大性心肌病 : 開發平台分析 Dilated Cardiomyopathy - Pipeline Review, H2 2016
出版日期: 2016年07月20日 內容資訊: 英文 60 Pages
簡介

所謂擴大性心肌病(DCM)是由於左心室的擴張或衰弱,造成將向液送往心臟的功能低落。依不同情況,心臟甚至會無法放鬆得到充分的血液。隨著時間的拉長也會影響到心臟的其他心室。

本報告提供全球各國治療擴大性心肌病用的開發中產品開發情形相關分析、彙整開發中產品的最新趨勢,及臨床實驗各階段產品一覽,再加上主要企業簡介、主要藥物概要(產品概要、功能機制、研究開發(R&D)的發展情形)、最新的產業趨勢等調查,並將結果概述為以下內容。

簡介

  • 分析範圍

擴大性心肌病概要

治療藥的開發

  • 擴大性心肌病開發中產品:概要
  • 擴大性心肌病開發中產品:比較分析

各企業開發中的擴大性心肌病治療藥

大學/研究機關研究中的擴大性心肌病治療藥

開發中產品的概要

  • 臨床實驗階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

擴大性心肌病治療藥:開發中的產品一覽(各企業)

擴大性心肌病治療藥:研究中的產品一覽(大學/研究機關)

擴大性心肌病開發治療藥的企業

  • Array BioPharma Inc.
  • Hemostemix Ltd
  • Kasiak Research Private Limited
  • Sanofi
  • Vericel Corporation

擴大性心肌病:治療藥的評估

  • 單劑治療藥的情況
  • 各標靶
  • 各行動機制
  • 各投藥法
  • 各分子類型

藥物簡介

  • ACP-01
  • ARRY-797
  • CAP-1002
  • 擴大性心肌病藥物
  • ixmyelocel-T
  • Refacell-DCM
  • 擴大性心肌病小分子

擴大性心肌病治療藥:最新的藥物簡介

擴大性心肌病治療藥:開發暫停的產品

擴大性心肌病相關產品的開發里程碑

  • 值得注意的最新趨勢、新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8247IDB

Summary

Global Markets Direct's, 'Dilated Cardiomyopathy - Pipeline Review, H2 2016', provides an overview of the Dilated Cardiomyopathy pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Dilated Cardiomyopathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Dilated Cardiomyopathy and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Dilated Cardiomyopathy
  • The report reviews pipeline therapeutics for Dilated Cardiomyopathy by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Dilated Cardiomyopathy therapeutics and enlists all their major and minor projects
  • The report assesses Dilated Cardiomyopathy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Dilated Cardiomyopathy

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Dilated Cardiomyopathy
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Dilated Cardiomyopathy pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Dilated Cardiomyopathy Overview
    • Therapeutics Development
  • Pipeline Products for Dilated Cardiomyopathy - Overview
  • Dilated Cardiomyopathy - Therapeutics under Development by Companies
  • Dilated Cardiomyopathy - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Dilated Cardiomyopathy - Products under Development by Companies
  • Dilated Cardiomyopathy - Companies Involved in Therapeutics Development
    • Array BioPharma Inc.
    • Capricor Therapeutics, Inc.
    • Hemostemix Ltd
    • Kasiak Research Private Limited
    • Sanofi
    • Vericel Corporation
  • Dilated Cardiomyopathy - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • ACP-01 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ARRY-797 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CAP-1002 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CIP-137401 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Drugs for Dilated Cardiomyopathy - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ixmyelocel-T - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MYK-491 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Refacell-DCM - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Dilated Cardiomyopathy - Dormant Projects
  • Dilated Cardiomyopathy - Product Development Milestones
    • Featured News & Press Releases
      • Apr 04, 2016: Results from Vericel Positive Phase 2b ixCELL-DCM Clinical Trial of Ixmyelocel-T Presented at ACC and Published in The Lancet
      • Mar 29, 2016: Vericel to Host Review of Positive Phase 2b ixCELL-DCM Trial Results Following American College of Cardiology 65th Annual Scientific Sessions
      • Mar 28, 2016: Vericel Announces Publication of Clinical Trial Rationale and Study Design for the Phase 2b ixCELL-DCM Trial of Ixmyelocel-T in Patients with Heart Failure Due to Ischemic Dilated Cardiomyopathy
      • Mar 10, 2016: Vericel Announces Positive Top-Line Results From Phase 2b ixCELL-DCM Clinical Trial of Ixmyelocel-T in Patients With Heart Failure Due to Ischemic Dilated Cardiomyopathy
      • Jan 29, 2015: Vericel Completes Patient Enrollment in Phase 2b ixCELL-DCM Clinical Study of Ixmyelocel-T
      • Dec 19, 2013: Aastrom Biosciences Granted Composition-of-Matter Patent for Ixmyelocel-T in Australia
      • Dec 17, 2013: Capricor Therapeutics Cleared to Begin Phase II Portion of ALLSTAR Clinical Trial with CAP-1002 in Patients Following Heart Attack
      • Apr 19, 2013: Aastrom Biosciences Announces First Patients Treated In IxCELL-DCM Clinical Study Of Ixmyelocel-T
      • Jun 06, 2012: Aastrom Presents Preclinical Data Of Ixmyelocel-T At 18th Annual International Society For Cellular Therapy Meeting
      • May 10, 2012: Treatment With Ixmyelocel-T Shows Improvement In Outcome Of Heart Failure Patients
      • May 07, 2012: Aastrom To Present Phase IIa Trial Results Of Ixmyelocel-T In Dilated Cardiomyopathy Patients At SCAI Scientific Sessions
      • Oct 03, 2011: Aastrom Receives European Composition-Of-Matter Patent For Ixmyelocel-T
      • Sep 19, 2011: Aastrom Announces Positive 12-Month Safety And Efficacy Data From IMPACT-DCM Phase II Clinical Trial For Ixmyelocel-T In Treatment Of Dilated Cardiomyopathy
      • Sep 14, 2011: Aastrom To Present 12-Month Data From IMPACT-DCM Phase II Clinical Trial For Ixmyelocel-T In Treatment Of Dilated Cardiomyopathy
      • May 17, 2011: Aastrom To Present Results From Two Studies of Ixmyelocel-T At International Society For Cellular Therapy Meeting
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Dilated Cardiomyopathy, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Comparative Analysis by Unknown Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Dilated Cardiomyopathy - Pipeline by Array BioPharma Inc., H2 2016
  • Dilated Cardiomyopathy - Pipeline by Capricor Therapeutics, Inc., H2 2016
  • Dilated Cardiomyopathy - Pipeline by Hemostemix Ltd, H2 2016
  • Dilated Cardiomyopathy - Pipeline by Kasiak Research Private Limited, H2 2016
  • Dilated Cardiomyopathy - Pipeline by Sanofi, H2 2016
  • Dilated Cardiomyopathy - Pipeline by Vericel Corporation, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Dilated Cardiomyopathy - Dormant Projects, H2 2016

List of Figures

  • Number of Products under Development for Dilated Cardiomyopathy, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top